Targeting HER2 in the management of potentially resectable gastric adenocarcinoma: what are oncologists waiting for?

References

• 1. Université Saint-Joseph. Epidemiology of gastric cancer. (2020). https://ezproxy.usj.edu.lb:4555/contents/epidemiology-of-gastric-cancer?search=gastric%20cancer&source=search_result&selectedTitle=6∼150&usage_type=default&display_rank=6
  Google Scholar
• 2. Université Saint-Joseph. Clinical features, diagnosis, and staging of gastric cancer. (2020). https://ezproxy.usj.edu.lb:4555/contents/clinical-features-diagnosis-and-staging-of-gastric-cancer?search=gastric%20cancer&source=search_result&selectedTitle=1∼150&usage_type=default&display_rank=1
  Google Scholar
• 3. Xiong B-H, Cheng Y, Ma L, Zhang C-Q. An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer. Cancer Invest. 32(6), 272–284 (2014).
  Medline CASGoogle Scholar
• 4. l-Batran SE, Homann N, Pauligk C et al. Perioperative therapy with FLOT vs ECF/ECX in locally advanced gastric adenocarcinoma.The ASCO Post. (2020). www.ascopost.com/News/59969
  Google Scholar
• 5. Becker K, Mueller JD, Schulmacher C et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7), 1521–1530 (2003).
  MedlineGoogle Scholar
• 6. Bang Y-J, Cutsem EV, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687–697 (2010).
  Medline CASGoogle Scholar
• 7. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25(33), 5287–5312 (2007).
  Medline CASGoogle Scholar
• 8. Qu J, Qu X. The predictors of response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer Biomark. 17(1), 49–54 (2016).
  Medline CASGoogle Scholar
• 9. Marx AH, Tharun L, Muth J et al. HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 40(6), 769–777 (2009).
  Medline CASGoogle Scholar
• 10. Orlova R, Beliak NP, Kutukova S et al. Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy. J. Clin. Oncol. 38(Suppl. 15), e16529–e16529 (2020).
  Google Scholar
• 11. Tong G, Li S, Lin L et al. Trastuzumab with FLOT regimen for the perioperative treatment of resectable HER2 + advanced gastric cancer: a retrospective study. Cancer Manag. Res. 12, 2481–2489 (2020).
  Medline CASGoogle Scholar
• 12. Hoffmann-La Roche. An open-label, multi-center study to evaluate the disease free survival rate of a perioperative combination of capecitabine (xeloda), trastuzumab (herceptin) and oxaliplatin (XELOX-trastuzumab) in patients with resectable gastric or gastro-esophageal junction adenocarcinoma. (2015). https://clinicaltrials.gov/ct2/show/study/NCT01130337
  Google Scholar
• 13. Yamashita-Kashima Y, Iijima S, Yorozu K et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin. Cancer Res. 17(15), 5060–5070 (2011).
  Medline CASGoogle Scholar
• 14. Hofheinz RD, Haag GM, Ettrich TJ, Borchert K, Kretzschmar A, Teschendorf C. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized Phase II trial of the AIO. J. Clin. Oncol. 38(Suppl. 15), 4502–4502 (2020).
  Google Scholar
• 15. Wagner AD, Grabsch HI, Mauer M et al. EORTC-1203-GITCG - the “INNOVATION”-trial: effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized Phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer 19(1), 494 (2019).
  MedlineGoogle Scholar
• 16. Kataoka K, Tokunaga M, Mizusawa J et al. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger study). Jpn J. Clin. Oncol. 45(11), 1082–1086 (2015).
  MedlineGoogle Scholar
• 17. Wang J, Saukel GW, Garberoglio CA, Srikureja W, Hsueh C-T. Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. J. Hematol. Oncol. 3(1), 31 (2010).
  MedlineGoogle Scholar
• 18. Okubo S, Takahashi T, Miyazaki Y et al. [A case of unresectable local recurrence of gastric cancer successfully resected after pre-operative chemotherapy with trastuzumab]. Gan To Kagaku Ryoho 42(12), 2094–2096 (2015).
  Medline CASGoogle Scholar
• 19. Nishino M, Hosoda Y, Okano M et al. [A case of HER2-positive advanced gastric cancer with a pathological complete response to neoadjuvant chemotherapy with S-1/CDDP/trastuzumab]. Gan To Kagaku Ryoho 42(12), 2043–2045 (2015).
  Medline CASGoogle Scholar
• 20. Kanaya N, Arata T, Tanakaya K, Yamasaki R, Aoki H, Takeuchi H. [A case of HER2-positive esophagogastric junction cancer treated by using a neoadjuvant chemotherapy regimen consisting of trastuzumab]. Gan To Kagaku Ryoho 41(12), 2285–2286 (2014).
  MedlineGoogle Scholar
• 21. Wakabayashi Y, Okuno A, Togawa A. [Complete response with neoadjuvant chemotherapy and curative resection in a case of locally advanced gastric cancer that was strongly positive for HER2 with multiple liver metastases]. Gan To Kagaku Ryoho 47(4), 621–624 (2020).
  MedlineGoogle Scholar
• 22. Dong C-X. Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy. World J. Gastroenterol. 20(34), 12355 (2014).
  Medline CASGoogle Scholar
• 23. Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin. Ther. 31(Pt 2), 2332–2348 (2009).
  Medline CASGoogle Scholar
• 24. Wainberg ZA, Anghel A, Desai AJ et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res. 16(5), 1509–1519 (2010).
  Medline CASGoogle Scholar
• 25. Hecht JR, Bang Y-J, Qin SK et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC – a randomized Phase III trial. J. Clin. Oncol. 34(5), 443–451 (2015).
  MedlineGoogle Scholar
• 26. Phase II study of neoadjuvant XELOX + lapatinib in HER2(+) gastric cancer patients with liver metastasis – tabular view. (2020). https://clinicaltrials.gov/ct2/show/record/NCT02015169
  Google Scholar
• 27. Smyth EC, Rowley S, Cafferty FH et al. Safety and efficacy of the addition of lapatinib to perioperative chemotherapy for resectable HER2-positive gastroesophageal adenocarcinoma: a randomized Phase 2 clinical trial. JAMA Oncol. 5(8), 1181–1187 (2019).
  MedlineGoogle Scholar
• 28. Foukakis T, Lundell L, Gubanski M, Lind PA. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol. Stockh. Swed. 46(3), 277–285 (2007).
  Medline CASGoogle Scholar
• 29. Magalhães H, Fontes-Sousa M, Machado M. Immunotherapy in advanced gastric cancer: an overview of the emerging strategies. Can. J. Gastroenterol. Hepatol. 2018, 1–8 (2018).
  Google Scholar